Trials / Completed
CompletedNCT04773977
Clinical Study of IBI362 in Healthy Chinese Male Subjects
Clinical Study to Evaluate the Pharmacokinetics and Safety of IBI362 Lyophilized Powder and IBI362 Liquid Formulation in Healthy Chinese Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- Male
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a study to evaluate the pharmacokinetic characteristics and safety of IBI362 lyophilized powder and IBI362 liquid formulation in healthy Chinese male subjects.
Detailed description
Pharmacokinetic；Safety
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI362 liquid formulation | Administered by subcutaneous injection |
| DRUG | IBI362 lyophilized powder | Administered by subcutaneous injection |
Timeline
- Start date
- 2021-03-03
- Primary completion
- 2021-03-09
- Completion
- 2021-06-17
- First posted
- 2021-02-26
- Last updated
- 2021-07-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04773977. Inclusion in this directory is not an endorsement.